REGULATORY

Japan Agrees to Buy 1.4 Million Doses of Daiichi Sankyo’s COVID Vaccine

November 17, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japanese government said on November 17 that it has agreed to buy 1.4 million doses of Daiichi Sankyo’s COVID-19 vaccine adapted to the Omicron XBB.1.5 variant, contingent on its regulatory approval. “This is our first purchase agreement for a…

To read the full story

Debut of Japan-Made COVID-19 Jab Is Momentous: Daiichi Sankyo President
November 29, 2023
Meiji’s mRNA Vaccine, Daiichi’s XBB.1.5 Jab Up for Nov. 27 PAFSC Session
November 17, 2023
Daiichi Sankyo Files XBB.1.5 COVID Jab, Eyes Japan Rollout by Year-End
September 8, 2023

REGULATORY

MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026
MHLW Sets Up Drug Discovery Support Office Ahead of New Fund Launch
January 6, 2026
Ex-JPMA President Ueno Takes on New AMED Advisor Role
January 6, 2026
Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…